CD274 and neoplasm: Mechanistically, PD-1 signaling acts as a brake to the immune system but it can be stopped by implementation of either PD-1 or PD-L1 blocking monoclonal antibodies that are able to directly inactivate the PD-L1 inhibitory signaling in TME, reverse T-cell exhaustion, and ultimately induce tumor regression (334, 335).